Prognostic value of HER2/neu expression in patients with prostate cancer: a systematic review

Moghadas niyat, Mozhgan (2015) Prognostic value of HER2/neu expression in patients with prostate cancer: a systematic review. Reviews in Clinical Medicine, 2 (4). pp. 168-173.

[img]
Preview
Text
RCM_Volume 2_Issue 4_Pages 168-173.pdf

Download (330kB) | Preview
Official URL: http://rcm.mums.ac.ir/article_4816.html

Abstract

Introduction: The prognostic value of Her2-positive expression has been investigated for malignancies such as breast cancer. We aimed to study the association between Her2 gene overexpression and clinical progression of hormone-independent prostate cancer. Methods: PubMed was searched to obtain the relevant articles without language or date limit. Reference list of the relevant articles was also searched to prevent missing any relevant article. Data were extracted regarding the patients’ survival and disease-free survival. Results: Overall, 15 articles were obtained, which studied the prognostic value of Her2 overexpression in patients with prostate cancer. Based on obtained hazard ratio and calculated log-rank test, overexpression of Her2 was significantly associated with disease recurrence, overall survival and cause-specific survival. Discussion: Her2 expression can be considered as a mortality rate indicator in patients with metastatic prostate cancer and higher risk of disease recurrence (increase in PSA level) has been suggested in these patients with over expression of Her2.Conclusion: Despite various differences in included articles regarding methodology, results, sample size and individual differences, Her2 overexpression showed a positive relation with poor prognosis of prostate cancer regarding survival and disease recurrence.

Item Type: Article
Subjects: QY Clinical Pathology
QZ pathology-Neoplasms
Divisions: Journals > Reviews in Clinical Medicine
Depositing User: RCM RCM
Date Deposited: 28 Sep 2017 15:40
Last Modified: 28 Sep 2017 15:40
URI: http://eprints.mums.ac.ir/id/eprint/6343

Actions (login required)

View Item View Item